Clinical significance of staphylococcus aureus with decreased vancomycin sensitivity and countermeasures
-
-
-
[1] Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin[J]. Lancet, 1997, 350(9092): 1670-1673. doi: 10.1016/S0140-6736(97)07324-8
[2] Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance[J]. Lancet Infect Dis, 2001, 1(3): 147-155. doi: 10.1016/S1473-3099(01)00091-3
[3] Casapao A M, Leonard S N, Davis S L, et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate staphylococcus aureus bloodstream infection[J]. Antimicrob Agents Chemother, 2013, 57(9): 4252-4259. doi: 10.1128/AAC.00380-13
[4] Howden B P, Ward P B, Charles P G, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility[J]. Clin Infect Dis, 2004, 38(4): 521-528. doi: 10.1086/381202
[5] Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility[J]. J Antimicrob Chemother, 1997, 40(1): 135-136. doi: 10.1093/jac/40.1.135
[6] Howden B P, Davies J K, Johnson P D, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications[J]. Clin Microbiol Rev, 2010, 23(1): 99-139. doi: 10.1128/CMR.00042-09
[7] Leonard S N, Rybak M J. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations[J]. J Antimicrob Chemother, 2009, 63(1): 155-160.
[8] Horne K C, Howden B P, Grabsch E A, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA[J]. Antimicrob Agents Chemother, 2009, 53(8): 3447-3452. doi: 10.1128/AAC.01365-08
[9] Maor Y, Hagin M, Belausov N, et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia[J]. J Infect Dis, 2009, 199(5): 619-624. doi: 10.1086/596629
[10] Rybak M J, Leonard S N, Rossi K L, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)[J]. J Clin Microbiol, 2008, 46(9): 2950-2954. doi: 10.1128/JCM.00582-08
[11] van Hal S J, Paterson D L. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates[J]. Antimicrob Agents Chemother, 2011, 55(1): 405-410. doi: 10.1128/AAC.01133-10
[12] Richter S S, Diekema D J, Heilmann K P, et al. Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States[J]. Antimicrob Agents Chemother, 2014, 58(2): 740-745. doi: 10.1128/AAC.01915-13
[13] Richter S S, Satola S W, Crispell E K, et al. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States[J]. J Clin Microbiol, 2011, 49(12): 4203-4207. doi: 10.1128/JCM.01152-11
[14] Charles P G, Ward P B, Johnson P D, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus[J]. Clin Infect Dis, 2004, 38(3): 448-451. doi: 10.1086/381093
[15] Howden B P, Johnson P D, Ward P B, et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia[J]. Antimicrob Agents Chemother, 2006, 50(9): 3039-3047. doi: 10.1128/AAC.00422-06
[16] Jacob J T, DiazGranados C A. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis[J]. Int J Infect Dis, 2013, 17(2): e93-e100. doi: 10.1016/j.ijid.2012.08.005
[17] Chen H B, Liu Y D, Sun W J, et al. The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC[J]. Diagn Microbiol Infect Dis, 2011, 71(3): 301-303. doi: 10.1016/j.diagmicrobio.2011.06.010
[18] Rose W E, Leonard S N, Rossi K L, et al. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model[J]. Antimicrob Agents Chemother, 2009, 53(2): 805-807. doi: 10.1128/AAC.01009-08
[19] Khatib R, Jose J, Musta A, et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia[J]. J Antimicrob Chemother, 2011, 66(7): 1594-1599. doi: 10.1093/jac/dkr169
[20] Fong R K, Low J, Koh T H, et al. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore[J]. Eur J Clin Microbiol Infect Dis, 2009, 28(8): 983-987. doi: 10.1007/s10096-009-0741-5
[21] Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin[J]. Antimicrob Agents Chemother, 2006, 50(4): 1581-1585. doi: 10.1128/AAC.50.4.1581-1585.2006
[22] Kelley P G, Gao W, Ward P B, et al. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure[J]. J Antimicrob Chemother, 2011, 66(5): 1057-1060. doi: 10.1093/jac/dkr066
[23] Vidaillac C, Steed M E, Rybak M J. Impact of dose de-escalation and escalation on daptomycin′s pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model[J]. Antimicrob Agents Chemother, 2011, 55(5): 2160-2165. doi: 10.1128/AAC.01291-10
[24] Leonard S N, Szeto Y G, Zolotarev M, et al. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA)[J]. Int J Antimicrob Agents, 2011, 37(6): 558-561. doi: 10.1016/j.ijantimicag.2011.02.007
[25] Steed M, Vidaillac C, Rybak M J. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model[J]. Antimicrob Agents Chemother, 2011, 55(7): 3522-3526. doi: 10.1128/AAC.00347-11
[26] Werth B J, Steed M E, Kaatz G W, et al. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect"[J]. Antimicrob Agents Chemother, 2013, 57(6): 2664-2668. doi: 10.1128/AAC.02308-12
[27] Dilworth T J, Leonard S N, Vilay A M, et al. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model[J]. Clin Ther, 2014, 36(10): 1334-1344. doi: 10.1016/j.clinthera.2014.06.027
[28] Peyko V, Smalley S, Cohen H. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin[J]. J Pharm Pract, 2017, 30(2): 209-213. doi: 10.1177/0897190016628960
计量
- 文章访问数: 246
- HTML全文浏览量: 122
- PDF下载量: 8
下载:
苏公网安备 32100302010246号
